Thursday 7th November 2019
Cancer genetic counseling

08:00 a.m.  Registration and coffee/tea
09:00 a.m.  Welcome

Session 1 – Polygenic risk scores and panel testing
09:10 a.m.  Antonis Antoniou (University of Cambridge, UK): Future-proofing breast cancer risk prediction
09:40 a.m.  Inge M.M. Lakeman (Leiden UMC, NL): Clinical applicability of the 313-SNP based polygenic risk score for breast cancer risk prediction
10:00 a.m.  Iris Kramer (NCI, Amsterdam, NL): Association between a breast cancer polygenic risk score and contralateral breast cancer risk
10:20 a.m.  Thomas P. Potjer (Leiden UMC, NL): Association between polygenic risk score and melanoma risk in 418 Dutch melanoma families
10:35 a.m.  Coffee/tea break
11:15 a.m.  Peter Devilee (Leiden UMC, NL): International Bridges-project on high-risk in non-carrier women

Session 2 – Psychosocial and counseling aspects
11:45 a.m.  D. Gareth Evans (Manchester University NHS FT, UK): Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender and time dependent is increased by having children
12:05 p.m.  Nicci Bartley (University of Sydney, AU): Fear of cancer recurrence and uncertainty in patients undergoing whole genome sequencing
12:25 p.m.  Caroline Willems and Désirée Hairwassers (Oncogen/ Breast Cancer Association, NL): What your patients didn't get
12:55 p.m.  Lunch break and poster sessions

02:00 p.m.  Eveline M.A. Bleiker (NCI, Amsterdam, NL): Implementing a tool to improve communication on psychosocial issues in cancer genetics
02:15 p.m.  Allison Werner-Lin (University of Pennsylvania, US): Complicated grief in family life with Li-Fraumeni Syndrome
02:30 p.m.  Miranda P. Steenbeek (Radboudumc, Nijmegen, NL): Worry and regret in the prospective multicentre TUBA study in BRCA1/2 mutation carriers
02:45 p.m.  Lieske H. Schrijver (NCI, Amsterdam, NL): Psychosocial issues in men tested for BRCA1/2 mutations

03:00 p.m.  Madeleine M.A. Tilanus-Linthorst (Erasmus MC, Rotterdam, NL): First benefit and cost of FaMRIsC, a RCT comparing mammography with MRI in screening for familial risk

03:15 p.m.  Marthe M. de Jonge (Leiden UMC, NL): Uterine cancer risk in women with germline BRCA1 and BRCA2 mutations

03:30 p.m.  Coffee/tea break

Session 3 – Mainstreaming of cancer genetics

04:15 p.m.  Michelle Bowman (Westmead Hospital, Sydney, AU): Mainstream genetic testing: Reflections on the first year at Westmead

04:30 p.m.  Sook-Yee Yoon (Cancer Research Malaysia, MY): Experiences with mainstreaming in Malaysia

05:00 p.m.  Kyra Bokkers (UMC Utrecht, NL): A gynecological oncologist-led mainstreaming approach of germline genetic testing for patients with ovarian cancer; first experiences of healthcare professionals and patients

05:15 p.m.  Heamanthaa Padmanabhan (Cancer Research Malaysia, MY): Decisional conflict, genetic counseling satisfaction and clinicians’ feedback from a mainstreaming BRCA1 and BRCA2 genetic testing study in Malaysia

05:30 p.m.  Closing

05:35 p.m.  Drinks

06:00 p.m.  Optional - CORPUS experience: ‘Journey through the human body’

07:30 p.m.  Buffet dinner
Friday 8th November 2019
Counseling aspects of hereditary cancer

08:00 a.m.  Registration and coffee/tea
09:00 a.m.  Welcome
09:10 a.m.  Elizabeth Bancroft (The Royal Marsden NHS Foundation Trust, London, UK): Germline predisposition to prostate cancer - clinical and psychosocial aspects

Session 1 – Lynch syndrome
09:40 a.m.  Albert S. Tjalsma (Erasmus MC, Rotterdam, NL): Implementation of a nationwide guideline to detect women at risk for Lynch Syndrome in endometrial cancer should be improved
10:00 a.m.  Karen Hurley (Cleveland Clinic, US): Time from genetic test result to first colonoscopy in Lynch patients with personal/family history of breast and/or gynecologic cancers
10:20 a.m.  Janet R. Vos (Radboudumc, Nijmegen, NL): Age related identification of Lynch Syndrome patients among patients with mismatch repair deficient colorectal cancer
10:40 a.m.  Coffee/tea break

Session 2 – Health literacy and family issues
11:25 a.m.  Margreet G.E.M. Ausems (UMC Utrecht, NL): Limited health literacy and access to cancer genetic counseling
11:55 a.m.  Fred H. Menko (NCI, Amsterdam, NL): The uptake of predictive DNA-testing in 40 BRCA1/BRCA2 mutation-positive families. An evaluation of the standard proband-mediated procedure
12:10 p.m.  Jeanine A.M. van der Giessen (UMC Utrecht, NL): Evaluation of a training program for healthcare professionals to improve communication about genetic testing with breast cancer patients with limited health literacy
12:30 p.m.  Wendy A.G. van Zelst-Stams (Radboudumc, Nijmegen, NL): Who is responsible for informing relatives of carriers: update of the Dutch guideline
12:45 p.m.  Maaike L. Haadsma (Radboudumc, Nijmegen, NL): Informing family members about predisposition for hereditary cancer: A proactive and personalized approach
01:00 p.m.  Lunch break and poster sessions
02:00 p.m.  Megan Best (University of Sydney, AU): Cancer patient knowledge and attitudes towards whole genome sequencing
Session 3 – Risk factors

02:15 p.m.  Karen Basen-Engquist (MD Anderson, Houston, US): Motivating change of lifestyle behavior in high risk families

02:45 p.m.  Daniele Giardiello (NCI, Amsterdam, NL): Prediction and clinical utility of a contralateral breast cancer risk model

03:05 p.m.  Mark van Barele (Erasmus MC, Rotterdam, NL): The association between radiotherapy and contralateral breast cancer risk in young BRCA1/2-associated breast cancer patients

03:20 p.m.  Frederieke van der Baan (NCI/UMC Utrecht, NL): Change of breast density after a risk reducing salpingo oophorectomy for BRCA1 and BRCA2 mutation carriers

03:40 p.m.  Coffee/tea break

04:20 p.m.  Jan Brouwer (UMC Groningen, NL): Risk factors for high-grade serous carcinoma in BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy – A preliminary report from the Dutch nationwide HEBON study

04:40 p.m.  Lise M. van Wijk (Leiden UMC, NL): Functional analysis of BRCAness in ovarian cancer

Session 4 – Future genetic testing

04:55 p.m.  Sibel Saya (University of Melbourne, AU): The acceptability and feasibility of assessing colorectal cancer risk using genomic testing to target screening in general practice

05:10 p.m.  Rolf Sijmons (UMC Groningen, NL): Direct to consumer testing, the way to go?

05:40 p.m.  Best poster awards

05:55 p.m.  Closing

06:00 p.m.  Drinks